Your browser doesn't support javascript.
loading
A Bayesian perspective on Biogen's aducanumab trial.
Temp, Anna G M; Ly, Alexander; van Doorn, Johnny; Wagenmakers, Eric-Jan; Tang, Yi; Lutz, Michael W; Teipel, Stefan.
Affiliation
  • Temp AGM; German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany.
  • Ly A; Translational Neurodegeneration Section "Albrecht Kossel," Department of Neurology, University of Rostock, Rostock, Germany.
  • van Doorn J; Department of Psychological Methods, University of Amsterdam, Amsterdam, the Netherlands.
  • Wagenmakers EJ; Machine Learning Group, Centrum Wiskunde & Informatica, Amsterdam, the Netherlands.
  • Tang Y; Department of Psychological Methods, University of Amsterdam, Amsterdam, the Netherlands.
  • Lutz MW; Department of Psychological Methods, University of Amsterdam, Amsterdam, the Netherlands.
  • Teipel S; Department of Neurology, Xuanwu Hospital, National Center for Neurological Disorders, Capital Medical University, Beijing, China.
Alzheimers Dement ; 18(11): 2341-2351, 2022 11.
Article in En | MEDLINE | ID: mdl-35235700
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Alzheimer Disease Type of study: Prognostic_studies Limits: Humans Language: En Journal: Alzheimers Dement Year: 2022 Document type: Article Affiliation country: Germany Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Alzheimer Disease Type of study: Prognostic_studies Limits: Humans Language: En Journal: Alzheimers Dement Year: 2022 Document type: Article Affiliation country: Germany Country of publication: United States